NEO
NeoGenomics, Inc. · Healthcare
7.99
0.31%(-0.03)
Market OpenLast Updated: — ET
52W L: $4.7252W H: $13.74
$7.99
CHG-0.62 (-7.20%)
H$9.72
L$7.06
VOL26M
NEO (1h)
NeoGenomics, Inc. · Healthcare
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its first quarter 2026 financial results after the close of the U.S. financial markets on Tuesday, April 28, 2026. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights. Beginning with Q1 2026, NeoGenomics will hold quarterly results calls.
Aberdeen Group plc boosted its stake in shares of NeoGenomics, Inc. (NASDAQ: NEO) by 127.1% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,798,939 shares of the medical research company's stock after buying an additional 1,006,676 shares during the quarter. Aberdeen
Shares of NeoGenomics, Inc. (NASDAQ: NEO - Get Free Report) have been given a consensus recommendation of "Hold" by the fourteen analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and five have issued a buy recommendation on the
Neo Performance Materials Inc. (NEO:CA) Q4 2025 Earnings Call Transcript
IRVINE, Calif.--(BUSINESS WIRE)--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced that its specialized aesthetic brand, “NEO Skin Clinic,” will open its flagship location in Tokyo's Ginza district, a globally recognized medical tourism hub and highly competitive district, on Saturday, March 28, 2026. The Ginza flagship, located i.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' PanTracer™ LBx test has received coverage from the Centers for Medicare & Medicaid Services' Molecular Diagnostics Services Program.
Stone Warren
officer: Pres & Chief Operating Officer
17,562 SH @ $0.00
2026-04-01
Stone Warren
officer: Pres & Chief Operating Officer
6,911 SH @ $0.00
2026-04-01
Stone Warren
officer: Pres & Chief Operating Officer
17,562 SH @ $0.00
2026-04-01
Zook Anthony P.
director, officer: Chief Executive Officer
140,498 SH @ $0.00
2026-04-01
Zook Anthony P.
director, officer: Chief Executive Officer
140,498 SH @ $0.00
2026-04-01
Zook Anthony P.
director, officer: Chief Executive Officer
45,453 SH @ $0.00
2026-04-01
Aunan Greg D
officer: Chief Accounting Officer
36,825 SH @ $9.83
2026-03-01
Aunan Greg D
officer: Chief Accounting Officer
22,889 SH @ $0.00
2026-03-01